Developer docs
API playgroundTry for free, no card

Search company profiles

Medi-Immune Ltd

Full company profile

uuid004vfll

Namestring
Medi-Immune Ltd
Websiteurl
medi-immune.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Medi-Immune Ltd is a United Kingdom-based micro-entity registered in Tamworth, Staffordshire, founded in 2008 and operating with approximately 6 employees. The company name suggests a healthcare or immunology orientation, though no products, services, or vertical positioning are documented in the available source material. The corporate website (https://www.medi-immune.com/) currently displays only a verification/loading screen and yields no extractable content on operations, products, customers, leadership, or financials.

No product catalog, pricing model, distribution channels, customer segments, partnerships, regulatory clearances, or strategic milestones are recorded in the input data. All enrichment fields — including headcount, technology stack, certifications, awards, funding rounds, M&A activity, and management team — are empty. The entity has no disclosed parent company, subsidiaries, investors, or public ticker, and no app or API footprint is documented.

The business model is therefore unverifiable from public sources provided. Given the 17-year operating history combined with a 6-person headcount and absence of any funding, M&A, or growth signals, the entity is most consistent with either a small inactive/dormant holding, a lifestyle consultancy, or an early-stage venture whose online presence has lapsed. No revenue, ARR, or transaction volume is disclosed. Any investment, partnership, or commercial thesis on this entity would require direct primary-source diligence (Companies House filings, direct management contact) before any characterization can be defended.

Short descriptiontext

Medi-Immune Ltd is a UK-based micro-entity (6 employees, founded 2008) in Tamworth, Staffordshire. Its product, service, customer base, and business model are unverifiable from current sources, as its website returns only a verification screen with no substantive content.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTamworth, Staffordshire, United Kingdom
HQ citystring
Tamworth, Staffordshire
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
immune health products, medical immunology, clinical diagnostics, healthcare supplies, therapeutic devices
Industry3 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Medical Immunology
Social media profiles1 record
Cost components1 value
Personnel
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Core offerings could not be determined; the company's website returned only a verification loading screen ("One moment, please...") and provided no product or service descriptions. The company name "Medi-Immune" suggests activity in medical or immunology-related fields, but no concrete offerings are evidenced.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available from the source data. The website displayed only a verification/loading page.

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing anti-FcRn antibodies for autoimmune diseases; comparable specialty immunology therapeutics peer.

TypeDirect peer
Description

Denmark-based antibody therapeutics company with a focus on immunology and oncology; directly comparable as an immunology/biologics specialty peer.

TypeDirect peer
Description

Swiss-based clinical-stage immunology company developing antibody-based therapeutics for inflammatory and immune-mediated diseases; comparable specialty immunology peer.

TypeDirect peer
Description

Clinical-stage immunology company developing antibody therapeutics for autoimmune diseases; comparable as a specialty immunology/antibody peer given Medi-Immune's name and likely positioning.

TypeBroad incumbent
Description

Nanobody-based immunology platform now part of Sanofi; comparable as an antibody/immunology specialty therapeutics peer with the broad-incumbent overlay.

TypeBroad incumbent
Description

Belgian specialty biopharmaceutical company with a deep immunology portfolio (e.g., Cimzia, Evenity) plus neurology; comparable as an established immunology-focused specialty pharma peer for a UK-anchored entity named in the immunology space.

TypeDirect peer
Description

UK-based clinical-stage biotech developing T cell engagers and immunology biologics; comparable UK-anchored, immunology-focused biotech peer.

8Immunomedics
TypeDirect peer
Description

Biopharmaceutical company developing antibody-drug conjugates for cancer and immune-mediated diseases; a relevant immunology/biologics peer.

TypeDirect peer
Description

Germany-based specialty biopharmaceutical company focused on immunology and hematology (plasma proteins, immunoglobulins); a relevant immunology specialty therapeutics peer.

10Kymab (Sanofi)
TypeBroad incumbent
Description

UK antibody discovery platform acquired by Sanofi; comparable as a UK-based immunology/antibody specialist peer.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medi-Immune Ltd

Medical Immunologymedi-immune.com

Medi-Immune Ltd is a UK-based micro-entity (6 employees, founded 2008) in Tamworth, Staffordshire. Its product, service, customer base, and business model are unverifiable from current sources, as its website returns only a verification screen with no substantive content.

What Medi-Immune Ltd does

Medi-Immune Ltd is a United Kingdom-based micro-entity registered in Tamworth, Staffordshire, founded in 2008 and operating with approximately 6 employees. The company name suggests a healthcare or immunology orientation, though no products, services, or vertical positioning are documented in the available source material. The corporate website (https://www.medi-immune.com/) currently displays only a verification/loading screen and yields no extractable content on operations, products, customers, leadership, or financials.

No product catalog, pricing model, distribution channels, customer segments, partnerships, regulatory clearances, or strategic milestones are recorded in the input data. All enrichment fields — including headcount, technology stack, certifications, awards, funding rounds, M&A activity, and management team — are empty. The entity has no disclosed parent company, subsidiaries, investors, or public ticker, and no app or API footprint is documented.

The business model is therefore unverifiable from public sources provided. Given the 17-year operating history combined with a 6-person headcount and absence of any funding, M&A, or growth signals, the entity is most consistent with either a small inactive/dormant holding, a lifestyle consultancy, or an early-stage venture whose online presence has lapsed. No revenue, ARR, or transaction volume is disclosed. Any investment, partnership, or commercial thesis on this entity would require direct primary-source diligence (Companies House filings, direct management contact) before any characterization can be defended.

Medi-Immune Ltd firmographics

Firmographics
Name
Medi-Immune Ltd
Website
https://medi-immune.com
Company type
Private
Founded year
2008
Headcount range
1–10 employees
Short description
Medi-Immune Ltd is a UK-based micro-entity (6 employees, founded 2008) in Tamworth, Staffordshire. Its product, service, customer base, and business model are unverifiable from current sources, as its website returns only a verification screen with no substantive content.
Ownership category
akta.pro rank

Medi-Immune Ltd industry classification

Industry
Product category
Medical Immunology
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immune health products
  • Medical immunology
  • Clinical diagnostics
  • Healthcare supplies
  • Therapeutic devices

Where Medi-Immune Ltd is headquartered

Location

Headquarters

HQ city
Tamworth, Staffordshire
HQ country
United Kingdom
HQ region
Europe

Markets served

Medi-Immune Ltd business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel

Medi-Immune Ltd product offering

Product offering

Core offering

Core offerings could not be determined; the company's website returned only a verification loading screen ("One moment, please...") and provided no product or service descriptions. The company name "Medi-Immune" suggests activity in medical or immunology-related fields, but no concrete offerings are evidenced.

Product overview

No product information available from the source data. The website displayed only a verification/loading page.

Differentiator

Problem solved

Functional benefit

Medi-Immune Ltd technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medi-Immune Ltd partnerships and signals

Strategic signal

Expansion highlights1 record

Medi-Immune Ltd competitors and assessment

Company assessment

Direct peers

  • Immunovant: Clinical-stage immunology company developing anti-FcRn antibodies for autoimmune diseases; comparable specialty immunology therapeutics peer.
  • Genmab: Denmark-based antibody therapeutics company with a focus on immunology and oncology; directly comparable as an immunology/biologics specialty peer.
  • Novimmune: Swiss-based clinical-stage immunology company developing antibody-based therapeutics for inflammatory and immune-mediated diseases; comparable specialty immunology peer.
  • Argenx: Clinical-stage immunology company developing antibody therapeutics for autoimmune diseases; comparable as a specialty immunology/antibody peer given Medi-Immune's name and likely positioning.
  • Crescendo Biologics: UK-based clinical-stage biotech developing T cell engagers and immunology biologics; comparable UK-anchored, immunology-focused biotech peer.
  • Immunomedics: Biopharmaceutical company developing antibody-drug conjugates for cancer and immune-mediated diseases; a relevant immunology/biologics peer.
  • Biotest: Germany-based specialty biopharmaceutical company focused on immunology and hematology (plasma proteins, immunoglobulins); a relevant immunology specialty therapeutics peer.

Broad incumbents

  • Ablynx (Sanofi): Nanobody-based immunology platform now part of Sanofi; comparable as an antibody/immunology specialty therapeutics peer with the broad-incumbent overlay.
  • UCB: Belgian specialty biopharmaceutical company with a deep immunology portfolio (e.g., Cimzia, Evenity) plus neurology; comparable as an established immunology-focused specialty pharma peer for a UK-anchored entity named in the immunology space.
  • Kymab (Sanofi): UK antibody discovery platform acquired by Sanofi; comparable as a UK-based immunology/antibody specialist peer.

Market position

Strengths1 record

Weaknesses3 records

Key risks4 records

Key highlights1 record

Customer concentration

Medi-Immune Ltd social profiles

Digital presence

Medi-Immune Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medi-Immune Ltd leadership team

Management profile

Number of profiles

Medi-Immune Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medi-Immune Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medi-Immune Ltd

What does Medi-Immune Ltd do?

Core offerings could not be determined; the company's website returned only a verification loading screen ("One moment, please...") and provided no product or service descriptions. The company name "Medi-Immune" suggests activity in medical or immunology-related fields, but no concrete offerings are evidenced.

When was Medi-Immune Ltd founded?

Medi-Immune Ltd was founded in 2008. It employs 1 to 10 people.

Where is Medi-Immune Ltd based?

Medi-Immune Ltd is headquartered in Tamworth, Staffordshire, United Kingdom, in the Europe region.

Who are Medi-Immune Ltd's main competitors?

Direct peers on record are Immunovant, Genmab, Novimmune, Argenx, Crescendo Biologics, Immunomedics and Biotest. Broad incumbents are Ablynx (Sanofi), UCB and Kymab (Sanofi).

Does Medi-Immune Ltd have an API?

No public API is recorded for Medi-Immune Ltd.

What industry is Medi-Immune Ltd in?

Medi-Immune Ltd's product category is Medical Immunology. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals